Boehringer Ingelheim Pharmaceuticals, Inc., recently announced the initiation of a trial to compare the safety, tolerability, and pharmacokinetics of adding pirfenidone (Esbriet) to treatment with OFEV (nintedanib, Boehringer Ingelheim) in patients with idiopathic pulmonary fibrosis (IPF). IPF, a type of interstitial lung disease affecting the tissue that supports the…
In a new study, researchers demonstrated the protective effects of vitamin D in a mouse model of pulmonary fibrosis induced by the chemotherapeutic drug bleomycin. The research paper, entitled “Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis,” was published in the Nature journal Scientific Reports. Vitamin…
aTyr Pharma Inc., a biotherapeutics company that discovers and develops medicines through its Physiocrine platform for the treatment of rare diseases, has announced the selection of a new Investigational New Drug (IND) candidate, an iMod.Fc molecule. The selected therapeutic molecule aims to aid in the management of severe fibrotic…
New data from the analysis of trial INPULSIS™-ON, describing the long-term efficacy and side-effects of OFEV in the treatment of idiopathic pulmonary fibrosis (IPF), was presented at the European Respiratory Society (ERS) International Congress 2015. IPF is a type of interstitial lung disease, affecting the tissue that supports the alveoli…
Get regular updates to your inbox.
